Pharmacogenetics Of Vinorelbine In Malignant Pleural Mesothelioma Patients

Status Completed

Clinical Trial Summary

This is a multicenter retrospective analysis .The aim of the present study is to investigate the molecular predictors of vinorelbine response in tumor samples of a series of MPM patients and evaluate the possible impact on clinical outcome. Sample size: around 150 patients based on the availability of tumor size

Clinical Trial Description

Vinorelbine has recently become an alternative option for palliation in selected pemetrexed-pretreated patients with malignant pleural mesothelioma (MPM). However, nowadays there are no definitive data about vinorelbine predictors of response in MPM patients. The identification of molecular predictors of effective therapy is important for maximizing therapeutic efficacy and minimizing useless treatment in cancer patients. In oncology a pharmacogenetic approach to customize the chemotherapy treatment according to individual as well as tumour genetic characteristics represents a modern and intriguing challenge. Recent studies have suggested that the expression levels of class III β-tubulin (TUBB3) or BRCA1, are related to a survival benefit from vinorelbine chemotherapy among patients with advanced solid malignancies, especially non-small cell lung cancer. There are no data about the predictive factors to vinorelbine in MPM patients. The identification of molecular predictors of effective therapy may allow in the future the development of better therapies. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01865045
Study type	Observational
Source	Istituto Clinico Humanitas
Contact
Status	Completed
Phase
Start date	November 2012
Completion date	December 2017

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06037941` - Using E-Nose Technology to Measure Response to Treatment in People With Malignant Pleural Mesothelioma	N/A
Completed	`NCT01675765` - Safety and Efficacy of Listeria in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural Mesothelioma	Phase 1
Withdrawn	`NCT04201145` - Pembrolizumab + Defactinib In Pleural Mesothelioma	Phase 1
Completed	`NCT03048474` - Ipilimumab and Nivolumab in the Treatment of Malignant Pleural Mesothelioma	Phase 2
Completed	`NCT02369198` - MesomiR 1: A Phase I Study of TargomiRs as 2nd or 3rd Line Treatment for Patients With Recurrent MPM and NSCLC	Phase 1
Terminated	`NCT01870609` - Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma	Phase 2
Active, not recruiting	`NCT00886028` - Palliative Treatment With Liposomal Doxorubicin Plus Cisplatin for Patients With Malignant Pleural Mesothelioma	Phase 2
Completed	`NCT00272558` - Study of Carboplatin and Vinorelbine in Malignant Pleural Mesothelioma	Phase 2
Active, not recruiting	`NCT02436733` - Pleurectomy/ Decortication (P/D) Preceded or Followed by Chemotherapy in Patients With Early Stage MPM	Phase 2
Completed	`NCT04843007` - Alvopem® (Pemetrexed) Safety Assessment
Completed	`NCT01721018` - Intrapleural Administration of HSV1716 to Treat Patients With Malignant Pleural Mesothelioma.	Phase 1/Phase 2
Active, not recruiting	`NCT00797719` - Short Neoadjuvant Hemithoracic IMRT for MPM	Phase 1/Phase 2
Completed	`NCT00386815` - Safety Confirmation Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma	Phase 2
Recruiting	`NCT03715933` - Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas	Phase 1
Completed	`NCT04775446` - Evaluation of the Clinical/Biological Characteristics, Efficacy and Safety of Patients With Malignant Pleural Mesothelioma, Treated by Immunotherapy
Completed	`NCT01644994` - Intracavitary Cisplatin-Fibrin Localized Chemotherapy After P/D or EPP for Malignant Pleural Mesothelioma	Phase 1/Phase 2
Completed	`NCT00571298` - Extrapleural Pneumonectomy /Pleurectomy Decortication, IHOC Cisplatin and Gemcitabine With Amifostine and Sodium Thiosulfate Cytoprotection for Resectable Malignant Pleural Mesothelioma	Phase 1
Recruiting	`NCT01343264` - Trimodality Therapy for Malignant Pleural Mesothelioma	N/A
Active, not recruiting	`NCT04162015` - A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma	Phase 1
Recruiting	`NCT04400539` - The IMmunotherapy Pleural 5-ALA PDT	Phase 2